

#### **ASX Announcement**

17 September 2019

#### ISSUES OF SECURITIES AND CLOSURE OF SHORTALL OFFER

Roots Sustainable Agricultural Technologies Ltd (ASX: ROO) attaches an Appendix 3B detailing the issue of securities approved at its General Meeting held on 11 September 2019.

In addition, the Company notes that the Shortfall Offer under the Entitlement Issue Prospectus dated 17 June 2019 has now closed.



Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

#### Name of entity

Roots Sustainable Agricultural Technologies Ltd

#### ARBN

619 754 540 - A Company Registered in Israel

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- +Class of +securities issued or to be issued
- 1. Listed Options
- 2. Listed Options
- 3. Listed Options
- 4. Performance Rights
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- 1. 5,073,810
- 2. 350,000
- 3. 3,000,000
- 4. 13,200,000
- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- Listed Options exercisable at \$0.12 on or before 24 July 2022 (ASX: ROOO)
- 2. Listed Options exercisable at \$0.12 on or before 24 July 2022 (ASX: ROOO)
- 3. Listed Options exercisable at \$0.12 on or before 24 July 2022 (ASX: ROOO)
- 4. Performance Rights (subject to vesting conditions)

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

- No Upon exercise and conversion into CDIs, the Options will rank equally with the existing class of CDIs on issue
- 2. No Upon exercise and conversion into CDIs, the Options will rank equally with the existing class of CDIs on issue
- 3. No upon exercise and conversion into CDIs, the Options will rank equally with the existing class of CDIs on issue
- 4. No Upon vesting and conversion into CDIs, the Performance Rights will rank equally with the existing class of CDIs on issue
- 1. Nil
- 2. \$0.04 per Option
- 3. Nil
- 4. Nil
- Free attaching Placement Options issued to participants in the Placement announced to ASX on 15 May 2019. Approved by shareholders at the General Meeting held 11 September 2019
- 2. Issue of listed options to related parties comprising the shortfall from the Option Entitlement Issue pursuant to the Prospectus lodged with ASX on 17 June 2019. The issue of the shortfall options was approved by shareholders at the General Meeting held 11 September 2019
- 3. Issue of Listed Options to Everblu Capital as approved by shareholders at the General Meeting held 11 September 2019, and detailed in the Notice of Meeting lodged with ASX on 7 August 2019
- 4. Issue of Performance Rights to Directors as approved by shareholders at the General Meeting held 11 September 2019, and detailed in the Notice of Meeting lodged with ASX on 7 August 2019

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h	Yes
	in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	23 May 2019
6c	Number of *securities issued without security holder approval under rule 7.1	nil
6d	Number of *securities issued with security holder approval under rule 7.1A	nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<ol> <li>5,073,810 Listed Options exercisable at \$0.12 on or before 24 July 2022 (ASX: ROOO)</li> <li>350,000 Listed Options exercisable at \$0.12 on or before 24 July 2022 (ASX: ROOO)</li> <li>3,000,000 Listed Options exercisable at \$0.12 on or before 24 July 2022 (ASX: ROOO)</li> <li>13,200,000 Performance Rights (subject to performance milestones)</li> </ol>
		Issue of the above securities approved by shareholders at the General Meeting held 11 September 2019.
6f	Number of *securities issued under an exception in rule 7.2	N/A
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A

<sup>+</sup> See chapter 19 for defined terms.

6h	If +se	ecurities v	vere	issu	ed ur	nder
	rule	7.1A	fo	r	non-	cash
	cons	ideration,	st	ate	date	on
	whic	h valuatio	n of	cons	idera	tion
	was	released	to	ASX	Ma	rket
	Anno	ouncemen	ts			

N/A			
1 1/11			


6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1	12,304,698
7.1A	8,835,318

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix



8 Number and +class of all +securities quoted on ASX (*including* the +securities in section 2 if applicable)

Number	+Class
70,542,804	CDIs
13,832,402	Listed Options (exercisable at \$0.12 each expiring 24 July 2022) (ASX: ROOO)

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
18,758,654	CDIs (subject to escrow until 6 December 2019)
1,625,000	Options exercisable at \$0.01 cents each expiring 30 November 2022 (Subject to vesting conditions)
602,500	Options exercisable at \$0.01 cents each expiring 17 June 2024 (Subject to vesting conditions)
1,935,484	Options exercisable at \$0.14 each expiring 19 August 2020
5,933,333	Performance Rights (Subject to Performance Milestones) (subject to escrow until 6 December 2019)
13,200,000	Performance Rights (Subject to Performance Milestones)
498,000	Replacement Convertible Notes

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

There is currently no dividend policy for the Company

## Part 2 - Pro rata issue

11	Is	security	holder	approval	N/A	
	req	uired?				

Is the issue renounceable or non-renounceable?

N/A

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

13	Ratio in which the *securities will be offered N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates
15	<sup>+</sup> Record date to determine N/A entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their
	entitlements are to be dealt with.
	Cross reference: rule 7.7.
19	Closing date for receipt of N/A acceptances or renunciations
20	Names of any underwriters N/A
21	Amount of any underwriting fee N/A or commission
22	Names of any brokers to the issue N/A
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A
		plying for quotation of securities
	s that have ticked box 34(a) onal securities forming a new	class of securities
	indicate you are providing the informat	

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders – To be advised when issued
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories – To be advised when issued 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

nuue	ntitles that have ticked box 34(b)				
38	Number of *securities for which *quotation is sought	N/A			
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A			
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A			
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment				
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)	N/A			
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number +Class			

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the †securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 17 September 2019

Company secretary

Print name: Sarah Smith

== == == ==

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure calculated	from which the placement capacity is	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	63,966,667	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an	1,650,000 Collateral CDIs issued 19 February 2019 (ratified by shareholders on 23 May 2019)	
exception in rule 7.2	1,752,500 CDIs issued 4 April 2019 (ratified by shareholders on 23 May 2019)	
Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	220,000 CDIs issued 4 April 2019 (ratified by shareholders on 23 May 2019)	
Number of partly paid +ordinary securities that became fully paid in that 12 month	66,666 CDIs issued on 4 April 2019 (Exception 4 to Listing Rule 7.2)	
period	15,221,430 CDIs issued 23 May 2019 (approved by shareholders on 23 May 2019)	
Note:  Include only ordinary securities here – other classes of equity securities cannot be	1,015,152 CDIs issued 3 June 2019 (approved by shareholders on 23 May 2019)	
added Include here (if applicable) the securities	1,111,112 CDIs issued 12 July 2019 (approved by shareholders on 23 May 2019)	
the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of	2,272,728 CDIs issued 27 August 2019 (approved by shareholders on 23 May 2019)	
securities on different dates as separate line items	1,076,924 CDIs issued 27 August 2019 (ratified by shareholders on 11 September 2019)	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period		
"A"	88,353,179	

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]

<sup>+</sup> See chapter 19 for defined terms.

<b>Multiply</b> "A" by 0.15	13,252,977	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	68,279 CDIs issued 4 April 2019	
<ul> <li>Under an exception in rule 7.2</li> </ul>	880,000 CDIs issued 25 July 2019	
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	948,279	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	13,252,977	
Note: number must be same as shown in Step 2		
Subtract "C"	948,279	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	12,304,698	
	Note: this is the remaining placement capacity under rule 7.1	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

re from which the placement  8,353,179  .10  Note: this value cannot be changed
.10
,835,315
f placement capacity under rule

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10  Note: number must be same as shown in Step 2	8,835,315	
Subtract "E"  Note: number must be same as shown in Step 3	Nil	
<i>Total</i> ["A" x 0.10] – "E"	8,835,315  Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.